Effects of submicron particles on formation of micron-sized particles during long-term storage of an interferon-beta-1a solution

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 347-351

  Bai, Shujun ^a   Murugesan, Yogapriya ^a   Vlasic, Milana ^a,b   Karpes, Lori B ^a   Brader, Mark L ^a  

^a BIOGEN   (United States)

^b HEWLETT PACKARD COMPANY   (United States)

Author keywords

Biopharmaceuticals characterization; Biotechnology; Circular dichroism; Particle size; Physical stability; Protein aggregation; Protein formulation

Indexed keywords

BETA1A INTERFERON;

ANALYSIS; ARTICLE; CIRCULAR DICHROISM; DRUG STORAGE; IMAGING; MICROFLOW DIGITAL IMAGING; NANOPARTICLE TRACKING ANALYSIS; PARTICLE SIZE; PROTEIN CONFORMATION; STORAGE TEMPERATURE;

EID: 84872488041     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23414     Document Type: Article

References (15)

1. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. 2009. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98(4):1201-1205.
2. Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO. 2011. Classification and characterization of therapeutic antibody aggregates. J Biol Chem 286(28):25118-25133.
3. Narhi LO, Jiang YJ, Cao S, Benedek K, Shnek D. 2009. A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 10(4):373-381.
4. Zolls S, Tantipolphan R, Wiggenhorn M, Winter G, Jiskoot W, Friess W, Hawe A. 2012. Particles in therapeutic protein formulations, part 1: Overview of analytical methods. J Pharm Sci 101(3):914-935.
5. Narhi LO, Schmit J, Bechtold-Peters K, Sharma D. 2012. Classification of protein aggregates. J Pharm Sci 101(2):493-498.
6. Malloy A. 2011. Count, size and visualize nanoparticles. Mater Today 14(4):170-173.
7. Filipe V, Hawe A, Jiskoot W. 2010. Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 27(5):796-810.
8. Huang CT, Sharma D, Oma P, Krishnamurthy R. 2009. Quantitation of protein particles in parenteral solutions using micro-flow imaging. J Pharm Sci 98(9):3058-3071.
9. Fan HH, Ralston J, Dibiase M, Faulkner E, Middaugh CR. 2005. Solution behavior of IFN-beta-1a: An empirical phase diagram based approach. J Pharm Sci 94(9):1893-1911.
10. Barnard JG, Singh S, Randolph TW, Carpenter JF. 2011. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: Insights into the roles of particles in the protein aggregation pathway. J Pharm Sci 100(2):492-503.
11. Filipe V, Kukrer B, Hawe A, Jiskoot W. 2012. Transient molten globules and metastable aggregates induced by brief exposure of a monoclonal IgG to low pH. J Pharm Sci 101(7):2327-2339.
12. Kiese S, Pappenberger A, Friess W, Mahler HC. 2010. Equilibrium studies of protein aggregates and homogeneous nucleation in protein formulation. J Pharm Sci 99(2):632-644.
13. Chi EY, Weickmann J, Carpenter JF, Manning MC, Randolph TW. 2005. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 94(2):256-274.
14. Tyagi AK, Randolph TW, Dong A, Maloney KM, Hitscherich C, Carpenter JF. 2009. IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98(1):94-104.
15. Liu L, Randolph TW, Carpenter JF. 2012. Particles shed from syringe filters and their effects on agitation-induced protein aggregation. J Pharm Sci 101(8):2952-2959.